Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 dichloride in metastatic CRPC
NCT01618370Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2012
- Primary completion
- Aug 2014
- Countries
- 19
01
Overview
A Phase 3 trial of radium-223 dichloride in prostate cancer (PCa), sponsored by Bayer. Started Jul 2012; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01618370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01618370.